新诊断老年多发性骨髓瘤的预后分层及治疗进展

doi:10.11904/j.issn.1002-3070.2022.01.016

摘要/Abstract

摘要： 多发性骨髓瘤是一种好发于中老年人的浆细胞恶性增殖性疾病,目前仍不可治愈,中位诊断年龄为69岁,50%以上的患者在诊断时年龄大于75岁。近年来新药的应用显著改善了多发性骨髓瘤患者的总生存期和无进展生存期,但标准方案并不能让老年多发性骨髓瘤患者受益,可能还会降低患者生活质量,增加死亡率。因此,精准的预后评估及危险度分层对于实施个体化治疗至关重要。本文就老年多发性骨髓瘤治疗特点、预后分层及治疗进展做一综述。

关键词: 多发性骨髓瘤, 脆弱, 老年评估, 自体干细胞移植, 调整治疗

Abstract: Multiple myeloma(MM)is a malignant proliferative disease of plasma cells that occur in middle-aged and elderly people.It is still incurable.The median diagnostic age is 69 years old,and more than 50% of patients are older than 75 years old at the time of diagnosis.In recent years,the application of new drugs has significantly improved the overall survival and progression-free survival of patients with MM,but the standard regimen does not benefit elderly MM patients,and may also reduce the quality of life and increase mortality.Therefore,the accurate prognostic assessment and risk stratification are essential for individualized treatment.This article reviews the treatment characteristics,prognostic stratification and treatment progress of MM in the elderly.

Key words: Multiple myeloma, Fragility, Elderly assessment, Autologous stem cell transplantation, Adjustment treatment

中图分类号:

R733.3

李玉军, 刘丽洋, 肖娟娟, 薛华. 新诊断老年多发性骨髓瘤的预后分层及治疗进展[J]. 实用肿瘤学杂志, 2022, 36(1): 84-88.

LI Yujun, LIU Liyang, XIAO Juanjuan, XUE Hua. Prognostic stratification and treatment progress in elderly patients with newly diagnosed multiple myeloma[J]. Journal of Practical Oncology, 2022, 36(1): 84-88.

参考文献

1 Cowan AJ,Allen C,Barac A,et al.Global burden of multiple myeloma:a systematic analysis for the global burden of disease study 2016[J].JAMA Oncol,2018,4(9):1221-1227.
2 Pilleron S,Sarfati D,Janssen-Heijnen M,et al.Global cancer incidence in older adults,2012 and 2035:a population-based study[J].Int J Cancer,2019,144(1):49-58.
3 Dimopoulos MA,San-Miguel J,Belch A,et al.Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma:updated analysis of POLLUX[J].Haematologica,2018,103(12):2088-2096.
4 Bringhen S,Offidani M,Palmieri S,et al.Early mortality in myeloma patients treated with first-generation novel agents thalidomide,lenalidomide,bortezomib at diagnosis:a pooled analysis[J].Crit Rev Oncol Hematol,2018,130:27-35.
5 Yong K,Delforge M,Driessen C,et al.Multiple myeloma:patient outcomes in real-world practice[J].Br J Haematol,2016,175(2):252-264.
6 Niesvizky R,Flinn IW,Rifkin R,et al.Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens[J].J Clin Oncol,2015,33(33):3921-3929.
7 Rasche L,Kortum KM,Raab MS,et al.The impact of tumor heterogeneity on diagnostics and novel therapeutic strategies in multiple myeloma[J].Int J Mol Sci,2019,20(5):1248.
8 Pawlyn C,Cairns D,Kaiser M,et al.The relative importance of factors predicting outcome for myeloma patients at different ages:results from 3894 patients in the Myeloma XI trial[J].Leukemia,2020,34(2):604-612.
9 Palumbo A,Bringhen S,Mateos MV,et al.Geriatric assessment predicts survival and toxicities in elderly myeloma patients:an International Myeloma Working Group report[J].Blood,2015,125(13):2068-2074.
10 Engelhardt M,Dold SM,Ihorst G,et al.Geriatric assessment in multiple myeloma patients:validation of the International Myeloma Working Group(IMWG)score and comparison with other common comorbidity scores[J].Haematologica,2016,101(9):1110-1119.
11 陈海敏,周帆,韦苇,等.93例70岁以上多发性骨髓瘤患者的临床特点及转归[J].中华血液学杂志,2017,38(9):744-748.
12 Zhong YP,Zhang YZ,Liao AJ,et al.Geriatric assessment to predict survival and risk of serious adverse events in elderly newly diagnosed multiple myeloma patients:a multicenter study in china[J].Chin Med J(Engl),2017,130(2):130-134.
13 Engelhardt M,Domm AS,Dold SM,et al.A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients[J].Haematologica,2017,102(5):910-921.
14 Milani P,Vincent RS,Merlini G,et al.N-terminal fragment of the type-B natriuretic peptide(NT-proBNP)contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma[J].Am J Hematol,2016,91(11):1129-1134.
15 Cook G,Royle KL,Pawlyn C,et al.A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma(UK Myeloma Research Alliance Risk Profile):a development and validation study[J].Lancet Haematol,2019,6(3):154-166.
16 Joao C,Geraldes C,Neves M,et al.Management of older and frail patients with multiple myeloma in the Portuguese routine clinical practice:Deliberations and recommendations from an expert panel of hematologists[J].J Geriatr Oncol,2020,11(8):1210-1216.
17 Lemieux C,Muffly LS,Rezvani A,et al.Outcomes with autologous stem cell transplant vs.non-transplant therapy in patients 70 years and older with multiple myeloma[J].Bone Marrow Transplant,2021,56(2):368-375.
18 Benboubker L,Dimopoulos MA,Dispenzieri A,et al.Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma[J].N Engl J Med,2014,371(10):906-917.
19 Fayers PM,Palumbo A,Hulin C,et al.Thalidomide for previously untreated elderly patients with multiple myeloma:meta-analysis of 1685 individual patient data from 6 randomized clinical trials[J].Blood,2011,118(5):1239-1247.
20 Zweegman S,van der Holt B,Mellqvist UH,et al.Melphalan,prednisone,and lenalidomide versus melphalan,prednisone,and thalidomide in untreated multiple myeloma[J].Blood,2016,127(9):1109-1116.
21 Stewart AK,Jacobus S,Fonseca R,et al.Melphalan,prednisone,and thalidomide vs melphalan,prednisone,and lenalidomide(ECOG E1A06)in untreated multiple myeloma[J].Blood,2015,126(11):1294-1301.
22 Palumbo A,Hajek R,Delforge M,et al.Continuous lenalidomide treatment for newly diagnosed multiple myeloma[J].N Engl J Med,2012,366(19):1759-1769.
23 Magarotto V,Bringhen S,Offidani M,et al.Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma[J].Blood,2016,127(9):1102-1108.
24 San MJ,Schlag R,Khuageva NK,et al.Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma[J].J Clin Oncol,2013,31(4):448-455.
25 Durie B,Hoering A,Abidi MH,et al.Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant(SWOG S0777):a randomised,open-label,phase 3 trial[J].Lancet,2017,389(10068):519-527.
26 O'Donnell EK,Laubach JP,Yee AJ,et al.A phase 2 study of modified lenalidomide,bortezomib and dexamethasone in transplant-ineligible multiple myeloma[J].Br J Haematol,2018,182(2):222-230.
27 Facon T,Lee JH,Moreau P,et al.Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma[J].Blood,2019,133(18):1953-1963.
28 Mateos MV,Cavo M,Blade J,et al.Overall survival with daratumumab,bortezomib,melphalan,and prednisone in newly diagnosed multiple myeloma(ALCYONE):a randomised,open-label,phase 3 trial[J].Lancet,2020,395(10218):132-141.
29 Facon T,Kumar SK,Plesner T,et al.Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone(D-Rd)versus lenalidomide and dexamethasone(Rd)in patients with newly diagnosed multiple myeloma(NDMM)ineligible for transplant(MAIA)[J].Blood,2018,132(Supplement 1):2.
30 Stege CAM,Nasserinejad K,van der Spek E,et al.Efficacy and tolerability of ixazomib,daratumumab and low dose dexamethasone(ixa dara dex)in unfit and frail newly diagnosed multiple myeloma(NDMM)patients;Results of the interim efficacy analysis of the phase II HOVON 143 study[J].Blood,2019,134(Supplement1):695.
31 Mina R,Larocca A,Offidani M,et al.Efficacy and safety of ixazomib induction and maintenance in newly diagnosed multiple myeloma patients according to the IMWG frailty score:a post-hoc analysis of the emn10-unito trial[J].Blood,2020,136(Supplement 1):44-45.
32 Bringhen S,Pour L,Benjamin R,et al.Progression-free survival(PFS)benefit demonstrated and quality of life(QoL)maintained across age and frailty subgroups with the oral proteasome inhibitor(PI)ixazomib vs placebo as post-induction maintenance therapy in non-transplant newly diagnosed multiple myeloma(NDMM)patients(Pts):Analysis of the TOURMALINE-MM4 phase 3 trial[J].Blood,2020,136(Supplement 1):30-31.
33 Cairns D,Pawlyn C,Royle K,et al.Frailty-adjusted therapy in transplant non-eligible patients with newly diagnosed multiple myeloma(FiTNEss):a UK myeloma research alliance study,Myeloma XIV[J].Blood,2019,134(Supplement1):3153.

[1]	赵颖欣, 秦玲. 二甲双胍与多发性骨髓瘤的研究进展[J]. 实用肿瘤学杂志, 2020, 34(5): 476-479.
[2]	李林，毛朝明，周建明，高健青. ¹⁸F-FDG PET-CT显像在多发性骨髓瘤中的影像表现[J]. 实用肿瘤学杂志, 2017, 31(3): 222-227.
[3]	李文君，郭艳秋，高玉娟综述，苏雁华审校. 多发性骨髓瘤骨病的机制研究及治疗进展[J]. 实用肿瘤学杂志, 2017, 31(3): 246-249.
[4]	赵郁，朱晓婷，王轶楠. ω-3多不饱和脂肪酸诱导多发性骨髓瘤细胞凋亡及抗增殖机制的研究[J]. 实用肿瘤学杂志, 2016, 30(6): 516-522.
[5]	操梅林, 徐燕丽, 张磊. 多发性骨髓瘤化疗后发生急性髓系白血病一例并文献复习[J]. 实用肿瘤学杂志, 2015, 29(6): 536-539.
[6]	陈艳, 刘爱春. 套细胞淋巴瘤研究进展[J]. 实用肿瘤学杂志, 2012, 26(4): 377-380.
[7]	王燕, 刘爱春. 多发性骨髓瘤的治疗进展[J]. 实用肿瘤学杂志, 2012, 26(2): 183-187.
[8]	白力允, 刘爱春. 血管免疫母细胞性T细胞淋巴瘤研究进展[J]. 实用肿瘤学杂志, 2011, 25(3): 293-296.
[9]	王(王争);周义林;张军盛;徐惠琴. 多发性骨髓瘤病人99m Tc-MIBI显像的临床价值[J]. 实用肿瘤学杂志, 2008, 22(05): 441-443.
[10]	丁汀;裘小萍;顾磊;王应贵;陈峪;陈兆军;蒋挺英. 多发性骨髓瘤血小板生成素及受体初步研究[J]. 实用肿瘤学杂志, 2005, 19(03): 178-180.
[11]	袁志军;肖立新;欧阳沙西. 多发性骨髓瘤并发肾脏损害误诊原因分析[J]. 实用肿瘤学杂志, 2002, 16(04): 267-268.
[12]	陆海波;孙秀威;于雁. 25例多发性骨髓瘤的诊治分析[J]. 实用肿瘤学杂志, 2002, 16(04): 303-304.